Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 0.09 | 0.07 | -0.01 |
| FCF Yield | -7.79% | -28.36% | -68.97% | -36.40% |
| EV / EBITDA | -11.60 | -3.15 | -0.90 | -1.08 |
| Quality | ||||
| ROIC | -81.77% | -58.43% | -55.46% | -38.32% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.41 | 0.89 | 0.65 | 0.85 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -6.07% | 12.18% | 25.68% | -5.35% |
| Safety | ||||
| Net Debt / EBITDA | 0.28 | 0.48 | 0.33 | 1.57 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -2,575.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |